[3H] sertraline binding to rat brain membranes.

Psychopharmacology (Berl)

Central Research Division, Pfizer Inc., Groton, CT 06340.

Published: April 1990

Tritiated sertraline, a radiolabeled form of a potent and selective inhibitor of serotonin uptake, was found to bind with high affinity to rat whole brain membranes. Characterization studies showed that [3H] sertraline binding occurred at a single site with the following parameters: KD 0.57 nM, Bmax 821 fmol/mg protein, nH 1.06. This binding was reversible; the dissociation constant calculated from kinetic measurements (KD 0.81 nM) agreed with that determined by saturation binding experiments. [3H] Sertraline binding in the presence of serotonin, paroxetine, fluoxetine or imipramine suggested competitive inhibition of binding (large increase in KD with little change in Bmax). The rank order of potency of inhibition of [3H] sertraline binding was similar to that of inhibition of serotonin uptake for known uptake inhibitors and the 1-amino-4-phenyltetralin uptake blockers. A marked decrease in ex vivo [3H] sertraline binding in the brain of rats 7 days after treatment with p-chloroamphetamine was consistent with the loss of serotonin uptake sites induced by this agent. The results of our study indicated that [3H] sertraline labels serotonin uptake sites in rat brain.

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF02243998DOI Listing

Publication Analysis

Top Keywords

[3h] sertraline
24
sertraline binding
20
serotonin uptake
16
rat brain
12
binding
8
brain membranes
8
uptake sites
8
[3h]
6
sertraline
6
uptake
6

Similar Publications

Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders.

Expert Opin Drug Metab Toxicol

August 2024

The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.

Article Synopsis
  • - The study aimed to create and validate a population pharmacokinetic model for oral olanzapine in pediatric Chinese patients to better tailor medication dosing for individuals aged 8-17 years.
  • - Researchers collected data from 269 patients to analyze how various demographics and medications influence olanzapine levels, ultimately finding a one-compartment model that factors in body weight and sex for dosage calculations.
  • - The developed model suggests specific doses for boys and girls based on weight and the presence of other medications, which could improve treatment efficacy for pediatric patients taking olanzapine.
View Article and Find Full Text PDF

PI3K/Akt/NF-κB signaling pathway regulates behaviors in adolescent female rats following with neonatal maternal deprivation and chronic mild stress.

Behav Brain Res

April 2019

School of Basic Medicine Science & Forensic Medicine, Hangzhou Medical College, Zhejiang, People's Republic of China. Electronic address:

The early-life aversive experiences are associated with the increased risk for adolescent neuropsychiatric disorders and neuroinflammation. So, we used neonatal maternal deprivation (NMD) and chronic mild stress (CMS) to build adolescent depression model and investigate the role of microglia activation, PI3K/Akt/NF-κB pathway in female rats. Pups in NMD group were separated from mothers for 3 h each day from postnatal day (PND) 2 to PND 21 and rats in CMS group were subjected to one mild stressor each day from PND 22 to PND 42.

View Article and Find Full Text PDF

The enhancement of GABAergic and monoaminergic neurotransmission has been the mainstay of pharmacotherapy and the focus of drug-discovery for anxiety and depressive disorders for several decades. However, the significant limitations of drugs used for these disorders underscores the need for novel therapeutic targets. Neuronal nicotinic acetylcholine receptors (nAChRs) may represent one such target.

View Article and Find Full Text PDF

The sigma-1 receptor chaperone located in the endoplasmic reticulum (ER) may be implicated in the mechanistic action of some antidepressants. The present study was undertaken to examine whether new antidepressant drugs interact with the sigma-1 receptor chaperone. First, we examined the effects of selective serotonin reuptake inhibitors (SSRIs) (fluvoxamine, paroxetine, sertraline, citalopram and escitalopram), serotonin and noradrenaline reuptake inhibitors (SNRIs) (duloxetine, venlafaxine, milnacipran), and mirtazapine, a noradrenaline and specific serotonergic antidepressant (NaSSA), on [(3)H](+)-pentazocine binding to rat brain membranes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!